PMID- 25203263
OWN - NLM
STAT- MEDLINE
DCOM- 20190327
LR  - 20190327
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 29
IP  - 8
DP  - 2014 Aug
TI  - The impact of pioglitazone on bladder cancer and cardiovascular events.
PG  - 555-8
LID - 10.4140/TCP.n.2014.555 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic condition with increasing prevalence 
      and severe complications. Thiazolidinediones have been marketed since 1997 and 
      are effective glucose-lowering drugs, but individual drugs within the class have 
      been linked to serious adverse effects that resulted in the removal of 
      troglitazone from the market, restrictions to rosiglitazone's use, and a warning 
      added to pioglitazone's label. In 2007, a meta-analysis linked rosiglitazone to 
      myocardial infarction (MI). Pioglitazone does not appear to share this risk. To 
      the contrary, pioglitazone may reduce risk for MI. However, retrospective 
      evaluations have increasingly linked pioglitazone to a higher risk of bladder 
      cancer that appears to be time- and dose-dependent. Pioglitazone remains a 
      medication appropriate for consideration in the management of T2DM; however, 
      clinicians and patients should weigh its risks compared with alternatives, with a 
      regular review of risks.
FAU - Lee, Esther J
AU  - Lee EJ
AD  - University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma, USA.
FAU - Marcy, Todd R
AU  - Marcy TR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant 
      Pharmacists
JID - 9013983
RN  - 0 (Hypoglycemic Agents)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
MH  - Myocardial Infarction/*epidemiology
MH  - Pioglitazone/*adverse effects
MH  - Risk
MH  - Urinary Bladder Neoplasms/*epidemiology
EDAT- 2014/09/10 06:00
MHDA- 2019/03/28 06:00
CRDT- 2014/09/10 06:00
PHST- 2014/09/10 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2019/03/28 06:00 [medline]
AID - 10.4140/TCP.n.2014.555 [doi]
PST - ppublish
SO  - Consult Pharm. 2014 Aug;29(8):555-8. doi: 10.4140/TCP.n.2014.555.